[A long-surviving patient with lung pleomorphic carcinoma treated with postoperative carboplatin and paclitaxel combination chemotherapy].
We presented the case of a 46-year-old man with no medical or family history but with a history of smoking 3 packs of cigarettes per day for the past 25 years. He was admitted to our hospital due to hemoptysis. Chest computed tomography revealed a tumor of right upper lung and interstitial pneumonia in the surrounding lung parenchyma. He was operated upon and diagnosed with stage IIB pleomorphic carcinoma of the lung with invasion of the chest wall. He underwent three courses of postoperative carboplatin (CBDCA) (area under the curve 5 on day 1, every 3 weeks and paclitaxel(PTX) (200 mg/m(2); day 1, every 3 weeks) combination chemotherapy. No recurrence was observed for a period of 760 days after the operation. According to previous reports, lung pleomorphic carcinoma is aggressive and has a poor prognosis. Further, the significance of chemotherapy in the management of this disease has not been established. Postoperative combination chemotherapy of CBDCA and PTX may result in a good prognosis for this disease.
Nakamura
Shingen
S
Dept. of Internal Medicine, Health Insurance Naruto Hospital.
Horiuchi
Noriaki
N
Katsura
Daisuke
D
Shichijo
Kana
K
Yoshida
Sumiko
S
Harada
Eiji
E
Matsushita
Takaya
T
Oshima
Yasushi
Y
Matsuzaki
Yasuyuki
Y
Tamaki
Yasutami
Y
Kimura
Shigeaki
S
Takeichi
Toshiaki
T
Fujimoto
Hiroshi
H
Masuda
Kazuhiko
K
Iwasaka
Naohito
N
Shinomiya
Sadao
S
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D013997:Time Factors; D014057:Tomography, X-Ray Computed
D016190:Carboplatin; D017239:Paclitaxel